Purpose The purpose of this study aimed to evaluate the efficacy of local injection of allogeneic platelet-derived growth factors in treatment of patients with tennis elbow. Patients and methods This study included 120 tennis elbow patients randomly divided into two groups. The patients were locally injected with allogeneic growth factors (treatment group) or with normal saline (control group). The outcomes were assessed using Patient-Related Tennis Elbow Evaluation (PRTEE) and quick Disabilities of the Arm, Shoulder and Hand (qDASH) scales. The clinical outcomes were accordingly classified as excellent, good and poor. The patient’s satisfaction and adverse effects were also recorded. Results There was no statistically significant difference between the two groups regarding the age, gender, dominant arm or the pre-injection scores. At three month follow-up, the reductions in the mean PRTEE and qDASH scores were 88.7% and 70.6% in the treatment group versus 21.8% and 14.9% in the control group, respectively. At the last follow-up, the outcomes in the treatment group were excellent in 85% of patients and good in 15%, versus 8% and 32% in the control group. Overall, 95% were satisfied in the treatment group compared to 25% in control group. Forty patients in the treatment group experienced mild transient post-injection pain. Conclusion This study strongly suggests that local injection of allogeneic platelet-derived growth factors could be a promising safe treatment option for tennis elbow with significant pain relief, functional improvement and patient’s satisfaction. Yet, additional larger studies are needed to assess the durability of these outcomes.

Background: The world is facing the new pandemic caused by SARS-COV2. The confrontation of this new pandemic necessitates study and analysis of the clinical and laboratory finding in such entity. Objectives: To discuss the clinical and hematological findings in pediatric patients with SARS-CoV-2 infection and to correlate these characters with the need for ICU admission. Patients and methods: This was a hospital record-based study, in which the clinical features and laboratory findings of 29 pediatric patients with confirmed COVID-19 infection were obtained from the medical records of admitted pediatric patients. Results: This study included 29 pediatric patients with confirmed COVID-19 infection. Six cases (20.7%) were admitted to pediatric ICU. The most common presenting symptoms were cough in 23 cases (79.3%) and fever in 19 cases (65.5%). There was a significant association between tachypnea and ICU admission; as 5 out of 6 ICU cases (83.3%) had tachypnea compared to none 0/23 (0.0%) of the non ICU patients (P < 0.001). The frequencies of lymphopenia and thrombocytopenia were higher among ICU patients (100.0% and 50.0% respectively) than the non ICU ones (39.1% and 8.7% respectively) (P < 0.05 for both). The median values of lymphocytes and platelets counts were significantly lower in ICU patients than those of non ICU patients (P=0.002 and 0.007 respectively). CRP values were higher in ICU patients compared to non ICU patients (P=0.011). Conclusion: Decreased lymphocyte count, thrombocytopenia and elevated CRP can be stood out as discriminative laboratory indices for early ICU admission.

No abstract

A 7 1 9 -A 8 1 3 A743 were based on the 2013 utilisation volume data. Other local specific considerations e.g. subsidized selling prices and co-payments were included in the analyses for an assumed size of eligible patients. Sensitivity analyses were conducted. Results: The adoption rates of BIAsp were assumed to increase from 23.6% in 2013 to 30% or 36.5% in 2018 for base case and upside scenario, respectively. In comparison to base case scenario, increases in adoption rate of BIAsp were associated with a cumulative increase up to slightly greater than S$ 2.02M in insulin acquisition cost but a potential cumulative net saving up to approximately S$0.92M in overall total costs over 5 years, attributing to subsidized selling price of BIAsp assuming it is included standard drug list and its significantly lower major hypoglycaemia risk, respectively. Cost savings were predicted for other complications. ConClusions: The wider adoption of BIAsp was predicted to result in net cost savings from patient perspective in Singapore. More cost saving would be estimated in analyses with reduced productivity loss from a societal perspective.

Background Maternal employment, particularly during the first 6 months after birth of an infant, has been identified in a number of studies as an important barrier to the continuation of breastfeeding to 6 months) Compelling evidence highlights the protective effect of breastfeeding for children and mothers, such as fewer infections, improved cognitive development , lower rates of child obesity , lower risk of postpartum depression , and lower rates of breast and ovarian cancer for the mother Aim Assess the relationship between mother's state of employment (working or not) and identify the relationship between characteristics of mother's employment on breast-feeding practice among mothers in Benha and October 6 university hospitals Subjects and methods Outpatient mothers in clinics of gynecology and pediatrics in childbearing period and have children of less than one year old (working and not working) the sample size was five hundred mothers, three hundred and eighty-four were working and one hundred and sixteen were not working. Conclusion Less than half of mothers (44.5%) practiced on demand breastfeeding, 96.6% gave pacifiers, most of them (73.4%) didn't express their breast milk during work hours, there was a decrease in breastfeeding times\day among most of the working mothers also 87.5% of them reported that there was increase in their infant morbidities.